US Patent

US11723898 — Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Method of Use · Assigned to Aragon Pharmaceuticals Inc · Expires 2041-01-14 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment using androgen receptor inhibitors.

USPTO Abstract

Described herein are methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment with androgen receptor inhibitors, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

Drugs covered by this patent

Erleada (apalutamide) · Johnson & Johnson

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4449`	—	Erleada
`U-4449`	—	Erleada

Patent Metadata

Patent number: US11723898
Jurisdiction: US
Classification: Method of Use
Expires: 2041-01-14
Drug substance claim: No
Drug product claim: No
Assignee: Aragon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.